BOLD — Boundless Bio Balance Sheet
0.000.00%
Last trade - 00:00HealthcareSmall Cap
- $86.13m
- -$18.75m
Annual balance sheet for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 73 | 66.7 | 121 |
| Prepaid Expenses | |||
| Total Current Assets | 74.6 | 68 | 124 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 3.1 | 7.73 | 4.58 |
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 114 | 76.8 | 130 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 3.87 | 7.73 | 9.36 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 3.96 | 10.6 | 9.36 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Unrealized Gain / Loss | |||
| Total Equity | 110 | 66.3 | 121 |
| Total Liabilities & Shareholders' Equity | 114 | 76.8 | 130 |
| Total Common Shares Outstanding |